We are delighted to announce the opening of our new office in Philadelphia, PA, USA. This location has a long history of pharmaceutical and biotechnology innovation, bringing together 5 children’s hospitals, 4 national cancer centres, 126 hospitals and many global industry leaders and start-up companies.
We are excited to carry on this tradition and to bring our innovative thinking, enthusiastic team and proprietary technology platform to enable our biotech and pharma partners to accelerate early development and to reduce the risks and costs of later phase trials, through intelligent design and execution of smarter efficacy studies.
The move is in conjunction with our global growth and continued investment in IAG’ infrastructure. In addition to the corporate headquarters in London, UK and operational offices in EU, the new office space in Philadelphia will enable IAG’ team to continue expansion of our global network of scientific and medical collaborators, while being within easy reach of our strategic partners.
“The decision to expand our presence into Philadelphia area was a logical step in our business growth strategy,” said Dr. Olga Kubassova, CEO. “The area is rich with diverse talent from well-known prestigious colleges and universities, as well as high-tech and biotech Fortune 500 companies. We have built strong relationships with top pharmaceutical companies located here. Now, we have the opportunity to further expand into the area and bring on more exciting projects as well as to attract local talent to join our dynamic team.”
Our contact details:
Telephone: +1 267 319 90 12
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com